Your session is about to expire
← Back to Search
Stem Cell Therapy
Allogeneic adipose derived mesenchymal stem cells for Ischemia Reperfusion Injury
Phase 1
Waitlist Available
Led By Tambi Jarmi, MD
Research Sponsored by Tambi Jarmi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
This trial will test if the investigational drug aMSCs can help treat IRI, a condition that can occur after a kidney transplant.
Eligible Conditions
- Ischemia Reperfusion Injury
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Serious Adverse Events (SAEs)
Trial Design
3Treatment groups
Experimental Treatment
Group I: Intra-arterial infusionExperimental Treatment1 Intervention
5 subjects will receive AMSCs via intra-arterial infusion only
Group II: Intra parenchymal injection & Intra-arterial infusionExperimental Treatment1 Intervention
5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion
Group III: Intra parenchymal injectionExperimental Treatment1 Intervention
5 subjects will receive AMSCs via direct injection into the kidney parenchyma only
Find a Location
Who is running the clinical trial?
Tambi JarmiLead Sponsor
Tambi Jarmi, MDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville
University Of Aleppo (Medical School)
University Of Al Hospital (Residency)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Intra-arterial infusion
- Group 2: Intra parenchymal injection & Intra-arterial infusion
- Group 3: Intra parenchymal injection
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger